Low Price Generic Viagra & Levitra

August 31st, 2007

Buy Vardenafil Levitra Online 20 mg – 20 pills $69.95
Best Drug Prices, FREE Consultations, Cheapest Pills, Complete Privacy, Fastest Worldwide Delivery.
www.SelectedLevitra.com

Buy Sildenafil Citrate Soft Tabs 50 mg – 30 pills $59.95
Best ED Pills Prices. Complete Guaranteed Privacy. No Waiting For Doctor. No Prescription Required.
www.SelectedSoftViagra.com

Buy Generic Sildenafil Citrate 100 mg – 60 pills $119.95
Reputable Online Pharmacy. Wide Selection Of ED Medicines. Lowest Pills Prices. Worldwide Shipping.
www.SelectedViagra.com

Buy Cheap Soft Tab Tadalafil 20 mg – 90 pills $199.95
Discount Online Pharmacy, FREE Online Consultation, Licensed Physicians, Complete Privacy, Worldwide Delivery.
www.SelectedSoftCialis.com

New Heart Attack Treatment Guidelines Stress Coordination

February 7th, 2010

There’s a message for doctors, hospitals and communities in new guidelines for treatment of coronary disease and heart attacks: Get organized.

Every community should have an organized system of emergency care for heart attacks, including programs to identify patients before they get to hospitals and strategies for getting them to medical centers equipped to perform artery-opening procedures, say the guidelines issued by the American Heart Association, the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions.

“The focus on integrated systems for patients with STEMI is important,” said Dr. Sidney C. Smith Jr., a professor of medicine at the University of North Carolina, a past president of the American Heart Association and co-chair of the group that wrote the guidelines. “It affects a large number of the population that have heart attacks and will improve their treatment for sure.”

STEMI is an acronym derived from the pattern seen on an electrocardiogram in the most severe form of heart attacks. The goal is to get a heart attack victim as quickly as possible to a medical center for what is formally called percutaneous coronary intervention (PCI) — insertion of a balloon-tipped catheter into a blocked heart artery to reopen the blood vessel, usually followed by implantation of a stent, a thin tube, to be sure it remains open.

“The general recommendation is to move a patient if at all possible directly to hospitals where they are able to do immediate angioplasty [PCI],” said Dr. Spencer B. King III, president of the St. Joseph’s Heart and Vascular Institute in Atlanta, a past president of the American College of Cardiology and co-chair of the guidelines group. “If that is not possible, then there should be very rapid transport to hospitals that do angioplasty.”

The guidelines include recommendations on changes in treatment of heart attacks and coronary disease based on new research findings. For example, stenting now is recommended in many cases where the left main coronary artery, which provides blood to the majority of the heart, is blocked.

“It was previously thought not advisable to do it, but to go directly to bypass surgery,” King said. “But evidence continues to build that for some patients with left main blockage, stenting should be considered.”

Several studies, notably one from Korea, found similar outcomes for stenting or surgery in treating left main artery blockage, King said.

Other technical issues covered by the guidelines include:
Recommendations on use of a powerful new clot-dissolving drug, prasugrel (Effient), as an alternative to clopidogrel (Plavix), commonly prescribed after PCI. The greater ability of the new drug to dissolve clots does carry an added danger of excessive bleeding.
Use of a wire threaded into the coronary artery to gauge whether build-up of plaque deposits are great enough to warrant PCI.
Use of aspiration thrombectomy, in which the clot causing a heart attack is sucked out before a stent is implanted.
Recommendations on use of blood thinners and clot-dissolvers before, during or after PCI.
Recommendations on the types of X-ray dye used to view the heart arteries during PCI in patients with chronic kidney disease.

“But the big recommendation is that we need to improve the system of how patients get into one hospital when they are having a heart attack and then get into another hospital, if necessary,” Smith said.

To eat less, your body may want you to eat slowly

January 24th, 2010

Your mother’s advice to slow down at meal time may have been wise after all: a new study suggests that shoveling down your food blocks the body’s natural appetite-control process.

“Most of us have heard that eating fast can lead to food overconsumption and obesity, and in fact some…studies have supported this notion,” Dr. Alexander Kokkinos, the lead researcher on the study, said in a written statement.

What has been missing, however, is biological evidence that a leisurely meal is better for appetite control, according to Kokkinos and his colleagues at Athens University Medical School in Greece and the Imperial College London in the UK.

To study the question, the researchers had 17 healthy men eat a generous portion of ice cream under two different conditions: in one, they ate the treat in two servings over 5 minutes; in the other, they ate it in small servings over 30 minutes.

Although the groups’ feelings of fullness and hunger did not seem to differ, the researchers found that when the men ate slowly, they showed higher blood levels of two hormones — peptide YY (PYY) and glucagon-like peptide 1 (GLP-1) — for roughly three hours after the meal.

Both PYY and GLP-1 are released from the digestive tract as a “fullness” signal to the brain, curbing appetite and calorie intake.

The findings, to be published in an upcoming issue of the Journal of Clinical Endocrinology & Metabolism, give more weight to the conventional wisdom that people should savor their food.

Some previous research has found that when people take the time to chew their food thoroughly and enjoy a meal, they tend to eat fewer calories than when they have that same meal at an eat-and-run pace.

The reasons for that have been unclear, however.

“Our study provides a possible explanation for the relationship between speed eating and overeating by showing that the rate at which someone eats may impact the release of gut hormones that signal the brain to stop eating,” Kokkinos said.

The findings are particularly relevant in a time when many people are relying on fast food and regularly eating on the run, according to Kokkinos. The study suggests that slowing down at meal time could aid appetite control, and ultimately weight control.

They are a possible scientific explanation for “the warning we were given as children that ‘wolfing down your food will make you fat,’” Kokkinos said.

Pneumonia Can Be Prevented – Vaccines Can Help

January 8th, 2010

Pneumonia is an infection of the lungs that is usually caused by bacteria or viruses. Globally, pneumonia causes more deaths than any other infectious disease, such as AIDS, malaria or tuberculosis. However, it can often be prevented with vaccines and can usually be treated with antibiotics or antiviral drugs.

Every 15 seconds, somewhere in the world, a child dies from pneumonia. Many of these deaths are preventable through vaccination and appropriate treatment.

What Is Pneumonia?

Pneumonia is an infection of the lungs that can cause mild to severe illness in people of all ages. Signs of pneumonia can include coughing, fever, fatigue, nausea, vomiting, rapid breathing or shortness of breath, chills, or chest pain. Certain people are more likely to become ill with pneumonia. This includes adults 65 years of age or older and children less than 5 years of age. People up through 64 years of age who have underlying medical conditions (like diabetes or HIV/AIDS) and people 19 through 64 who smoke cigarettes or have asthma are also at increased risk for getting pneumonia.

Causes

When bacteria, viruses or, rarely, fungi living in your nose, mouth, sinuses, or the environment spread to your lungs, you can develop pneumonia or other infections. You can catch the bacteria or viruses from people who are infected with them, whether they are sick or not.

Types of Pneumonia

You may have heard of community-acquired pneumonia (CAP). When someone who hasn’t recently been in the hospital or another healthcare facility develops pneumonia, it’s called community-acquired.

Pneumonia is associated with healthcare when someone gets the infection during or following a stay in a healthcare facility (like hospitals, long-term care facilities, and dialysis centers). These infections are labeled healthcare-associated pneumonias, which includes healthcare-associated pneumonia (HCAP), hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP).

In the U.S., the most common bacterial cause of pneumonia is Streptococcus pneumoniae (pneumococcus) and the most common viral causes are influenza, parainfluenza, and respiratory syncytial viruses. In children less than 1 year of age, respiratory syncytial virus (RSV) is the most common cause of pneumonia. Other common bacterial and viral causes of pneumonia in the U.S. include Staphylococcus aureus and adenovirus. Pneumocystis jirovecii, a fungus formerly known as Pneumocystis carinii, is a common cause of pneumonia in patients with AIDS.

Reduce Your Risk

Pneumonia can be prevented with vaccines. Following good hygiene practices can also help prevent respiratory infections. This includes washing your hands regularly, cleaning hard surfaces that are touched often (like doorknobs and countertops), and coughing or sneezing into a tissue or into your elbow or sleeve. You can also reduce your risk of getting pneumonia by limiting exposure to cigarette smoke and treating and preventing conditions like diabetes and HIV/AIDS.

In the U.S., there are several vaccines that prevent infection by bacteria or viruses that may cause pneumonia. These vaccines include:
Pneumococcal,
Haemophilus influenzae type b (Hib),
Pertussis (whooping cough),
Varicella (chickenpox),
Measles; and
Seasonal and 2009 H1N1 influenza (flu) vaccines.
National and Global Impact

In 2006, 1.2 million people in the U.S. were hospitalized with pneumonia and 55,477 people died from the disease.

Globally, pneumonia kills more than 4 million people every year – half of these deaths occur among children less than 5 years of age. This is greater than the number of deaths from any other infectious disease, such as AIDS, malaria or tuberculosis. Access to vaccines and treatment (like antibiotics and antivirals) can help prevent many pneumonia-related deaths. Pneumonia experts are also working to prevent pneumonia in developing countries by reducing indoor air pollution and encouraging good hygiene practices.

Noise Hurts Men’s Hearing More, Study Shows

December 23rd, 2009

New research suggests that men — especially married white men — are much more likely to develop noise-induced hearing loss than women. But there’s some good news: Another study finds that older men who take high doses of folate can decrease their risk of hearing loss by 20 percent.

The figures regarding hearing loss in men and women come from a study of hearing-test data from 5,290 people aged 20 to 69. An estimated 13 percent of them will suffer from noise-induced hearing loss, which researchers think affects about 24 million Americans.

The condition, caused by exposure to loud noise, is preventable.

Among the subjects, men were two-and-a-half times more likely than women to develop this type of hearing loss. Married, non-Hispanic white men had the highest risk, the study authors pointed out.

In another study, researchers found that increased doses of antioxidant vitamins don’t improve a man’s chances of avoiding hearing loss. But folate — a type of vitamin B — reduced the risk by 20 percent in men older than 60.

The findings came from a study of 3,559 men with hearing loss. Higher doses of antioxidant vitamins, such as vitamins C, E and beta carotene, had no effect, the researchers said.

Foods with high levels of folate include leafy vegetables such as spinach, lettuce and asparagus; dried or fresh beans; peas; liver products; and fortified cereal products.

The researchers pointed out that their study is the largest to look into links between diet and hearing loss.

Routine Testing Would Improve Herceptin Use in Breast Cancer

December 1st, 2009

New research suggests that the anti-breast cancer drug trastuzumab, also known as Herceptin, isn’t reaching its full potential. Many patients aren’t receiving tests that determine whether it’s appropriate or are taking it when they don’t need to.

Under current guidelines, women with breast cancer in its early stages should receive tests to see if Herceptin might be appropriate for them.

In the new study, researchers analyzed medical data to see if testing has become routine. Their findings will appear in the Nov. 15 issue of the journal Cancer.

As many as two-thirds of patients who were eligible for the testing didn’t appear to have had it. And about 20 percent of those who did take the drug appeared to have not taken the test to see if it could work for them in the first place, the researchers found.

In another complication, the research suggests that about one in five tests is inaccurate.

Filling the gaps in care “may help optimize limited health-care resources and improve care for women with breast cancer,” said study co-author Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York, in a news release from the journal’s publisher.

Doctors are increasingly trying to fine-tune treatments so they specifically target the disease in a particular patient, the researchers noted.

Routine Testing Would Improve Herceptin Use in Breast Cancer

December 1st, 2009

New research suggests that the anti-breast cancer drug trastuzumab, also known as Herceptin, isn’t reaching its full potential. Many patients aren’t receiving tests that determine whether it’s appropriate or are taking it when they don’t need to.

Under current guidelines, women with breast cancer in its early stages should receive tests to see if Herceptin might be appropriate for them.

In the new study, researchers analyzed medical data to see if testing has become routine. Their findings will appear in the Nov. 15 issue of the journal Cancer.

As many as two-thirds of patients who were eligible for the testing didn’t appear to have had it. And about 20 percent of those who did take the drug appeared to have not taken the test to see if it could work for them in the first place, the researchers found.

In another complication, the research suggests that about one in five tests is inaccurate.

Filling the gaps in care “may help optimize limited health-care resources and improve care for women with breast cancer,” said study co-author Dr. Elena Elkin, a researcher at Memorial Sloan-Kettering Cancer Center in New York, in a news release from the journal’s publisher.

Doctors are increasingly trying to fine-tune treatments so they specifically target the disease in a particular patient, the researchers noted.

Quick Check That Could Save Your Grandparents’ Lives

November 13th, 2009

Sunday, September 13, is National Grandparents Day, and the American Academy of Dermatology (Academy) recommends that people lovingly remind their grandparents to perform a skin self-examination. Simply provide your grandparents with the Academy’s free tools to help them examine their skin for any suspicious lesions that could be cancerous. It’s an easy way to detect the only cancer that can be seen on the surface of a person’s skin.

Based on current estimates, substantially more than 1 million new cases of skin cancer are diagnosed in the United States every year. Melanoma, the deadliest form of skin cancer, is being diagnosed more rapidly in men age 65 and older than in the general population. A history of exposure to UV rays is a risk factor for skin cancer.

The Academy has created several tools to make it easy to determine if a mole is suspicious and should be brought to a dermatologist’s attention. The Academy’s Body Mole Map is a tool individuals can use to track their moles. The map provides information on how to perform a skin exam, images of the ABCDEs of melanoma and space for people to track their moles to determine any changes over time. The mole map is downloadable at no cost at www.aad.org/checkspot.

“Performing these checks regularly can help determine if a mole seems to be changing, which could be a sign of skin cancer,” said dermatologist David M. Pariser, MD, FAAD, president of the Academy. “Early detection is a key factor in the fight against skin cancer and ultimately can help save lives.”

One American dies of melanoma every hour (every 61 minutes). The five-year survival rate for people whose melanoma is detected and treated before it spreads to the lymph nodes is 99 percent. For more information about skin cancer, please visit the SkinCancerNet section of www.skincarephysicians.com, a Web site developed by dermatologists that provides patients with up-to-date information on the treatment and management of disorders of the skin, hair and nails.

Headquartered in Schaumburg, Ill., the American Academy of Dermatology (Academy), founded in 1938, is the largest, most influential, and most representative of all dermatologic associations. With a membership of more than 16,000 physicians worldwide, the Academy is committed to: advancing the diagnosis and medical, surgical and cosmetic treatment of the skin, hair and nails; advocating high standards in clinical practice, education, and research in dermatology; and supporting and enhancing patient care for a lifetime of healthier skin, hair and nails.

Reflux Drugs OK With Blood Thinners

November 13th, 2009

Antacids don’t interfere with anti-clotting drugs such as Plavix and Effient in patients who have suffered a heart attack or unstable angina, a new study finds.

The results counter other studies that concluded that a class of antacids known as proton pump inhibitors (PPIs) could block the effect of anti-clotting drugs. Doctors often prescribe PPIs along with anti-clotting drugs to reduce the risk of gastrointestinal bleeding.

“The current findings provide some reassurance to clinicians that PPIs and clopidogrel [Plavix] can be safely combined in patients in whom there is a strong indication to use both drugs,” said lead researcher Dr. Michelle O’Donoghue, an investigator in the TIMI Study Group at Brigham and Women’s Hospital in Boston.

As to why the findings differ from earlier results, O’Donoghue said the answer may lie in the patients themselves and in the type of data analyzed.

“Patients who are treated with a PPI may differ quite markedly from other patients,” she said. “In particular, there is concern that PPIs are often administered to sicker patients and that this may help to explain why patients on a PPI seem to do more poorly than other patients.”

In the current study, the researchers adjusted for these differences, O’Donoghue said.

“Another advantage of the current study is that it was done within the confines of a clinical trial,” she said. “In a clinical trial, all endpoints are strictly defined and adjudicated so there may be less of a risk for bias.”

The report is published in the Sept. 1 online edition of The Lancet, to coincide with the presentation of the results Monday at the European Society of Cardiology Congress in Barcelona.

For the study, O’Donoghue’s group looked at the effects of PPIs like Prilosec in two trials, the TRITON-TIMI 38 trial and a smaller trial. In the TRITON-TIMI 38 trial, researchers randomly assigned 13,608 patients to clopidogrel (Plavix) or prasugrel (Effient) after having a heart attack or unstable angina.

Giving the PPIs in combination with anti-clotting drugs did not increase the risk of death, heart attack, or stroke, the researchers concluded.

“We did not find use of a PPI to be associated with a higher risk of cardiovascular events for patients taking either clopidogrel or prasugrel,” O’Donoghue said.

Dr. Dirk Sibbing, from the Technische Universitat Munchen in Germany and co-author of an accompanying commentary, said this study shows that PPIs affect the anti-clotting drugs, but not patient outcomes.

“It seems that patients who carry a risk profile comparable to that of patients enrolled in TRITON-TIMI 38 can be safe on PPI treatment as long as compliance to regular anti-platelet drug intake is well-controlled,” Sibbing said.

However, cautions should remain for high-risk patients and those who are less responsive to Plavix, Sibbing said. Also, he said he believes that for some patients taking Effient and PPIs, the combination may be harmful, he said.

“In any case, monitoring of compliance to anti-platelet treatment is mandatory in all patients, but specifically in the group of patients under concomitant PPI treatment,” Sibbing said.

“Specific studies, however, are warranted in this group of patients to clarify this issue,” he said.

O’Donoghue doesn’t disagree. “In the end, only a randomized clinical trial can definitively demonstrate the safety of combining these two classes of drugs,” she said.

Studies To Date Say Erectile Dysfunction Drugs Affect Other Systems, Mostly For The Better

July 9th, 2008

Since the Food and Drug Administration gave Viagra (sildenafil) its approval in 1998, “erectile dysfunction” has become a household term – probably to the chagrin of many parents fielding questions from their kids watching TV. But with sildenafil and the subsequent introduction and marketing of Levitra- (vardenafil) and Cialis- (tadalafil), many men have found answers to a once-unmentionable condition.

“As more and more patients seek therapy for sexual dysfunction, it is increasingly important for clinicians in a wide range of specialties to become proficient in the mechanisms and systemic effects of these medications,” said Ernst R. Schwarz, M.D., Ph.D., a cardiologist at Cedars-Sinai Medical Center who specializes in therapies for men who suffer from erectile dysfunction (ED) and have heart problems, diabetes, high blood pressure or other related conditions.

Schwarz and colleagues recently concluded a review of the medical literature, as well as their own research findings and clinical data, to determine what actually is known about the effects of long-term use of this class of drugs on various organ systems. Their findings appears in the June, 2006 issue of the International Journal of Impotence Research.

Studies so far suggest the drugs, called phosphodiesterase-5 inhibitors (PDE-5i), produce mostly beneficial results, and not just for erectile dysfunction. The FDA recently approved a reformulation of sildenafil for the treatment of primary pulmonary hypertension, a disease that tends to occur in young women, causing elevated blood pressures in the lung that can lead to heart failure and early death.

“When we look at all the different organ systems – the blood, the heart, the lungs, blood flow in the brain – there are hardly any negative side effects. In fact, just the opposite is true. There are beneficial effects for primary pulmonary hypertension, as well as for conditions such as heart failure and lack of oxygen in the heart,” said Schwarz. “The only issue is that the data we have are from relatively short-term studies. Viagra has been on the market since 1998 and the other two PDE-5 inhibitors were approved by the FDA in 2003. Therefore, we do not have multi-year follow-up studies. On the other hand, the drugs have been on the market for several years now and there have been no reports of negative long-term effects.”

While there are some differences among the three medications, they have many properties in common and work by limiting the activity of the enzyme phosphodiesterase-5, which is found in tissues and vessels of the penis, blood platelets, and smooth muscle of blood vessels. For the treatment of erectile dysfunction, the drugs’ constraint of the enzyme’s action results in increased levels of cyclic guanosine monophosphate (cGMP) and nitric oxide (NO), biochemicals that promote smooth muscle relaxation and increased blood flow in erectile tissue.

According to the article, PDE-5 inhibitors can be effective in treating erectile dysfunction even for many men who also have diabetes, those who are older, and those who have co-existing ischemic heart disease (reduced blood flow to the heart caused by plaque buildup in the arteries). Furthermore, say the authors, “since PDE-5 is found in smooth muscles of the systemic arteries and veins throughout the body, use of PDE-5i has been associated with various cardiovascular effects.”

“The original intention was to develop PDE-5 inhibitors as a treatment for angina, chest pain that occurs when the heart is starved for oxygen,” Schwarz said. “As such, their effects on the heart appear to be all beneficial. Nitrates and other substances commonly used to improve blood flow and oxygenation to the heart muscle have a side effect that we call the ’steal phenomenon,’ in which blood is taken away from underperfused (flow-restricted) areas to improve blood flow in normal areas. In contrast, PDE-5 inhibitors actually improve blood flow even in areas where there is a blockage of an artery, thereby having a protective effect on the heart muscle.”

The drugs’ potential impact on visual function became a matter of controversy when a suspected link between PDE-5 inhibitors and vision loss led to lawsuits filed last year against the maker of Viagra. According to the article’s authors, however, “analysis of clinical trial data in more than 13,000 men and on more than 35,000 patient-years of observation” found occurrence of the visual disorder to be similar to that of the general population. “Even though individual cases have been reported for all PDE-5i, these recently published data do not suggest an increased incidence of NAION (non-arteric anterior ischemic optic neuropathy) in men who took PDE-5i for ED,” the article states.

Among other findings:

* Although the enzyme PDE-5 has been found in tissue and arteries of the brain, sildenafil does not appear to dilate cerebral arteries or have an effect on cerebral blood flow or blood flow velocity, an indication that there is no increased risk of stroke or hemorrhage.
* PDE-5 exists in blood platelets, cells that play a major role in the blood clotting process, but sildenafil appears to have no direct impact on platelet function. However, the drug’s effects have not been specifically evaluated in patients with bleeding disorders or in those taking drugs that reduce clotting.

“Experimental and human studies indicate that PDE-5 inhibitors are effective and well tolerated, and there is evidence that they are not being used to their utmost potential. We suggest that these drugs may prove beneficial in treating a wide variety of disorders,” said Schwarz, the article’s first author and a specialist in cardiology, interventional cardiology, heart failure, and transplantation. “Some studies are underway to determine the effects of long-term use of PDE-5 inhibitors, and others are warranted, especially in patients who are considered at high risk because of chronic cardiovascular disorders.”

The first of eight hospitals in California whose nurses have been honored with the prestigious Magnet designation, Cedars-Sinai Medical Center is one of the largest nonprofit academic medical centers in the Western United States. For 18 consecutive years, it has been named Los Angeles’ most preferred hospital for all health needs in an independent survey of area residents. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. It ranks among the top 10 non-university hospitals in the nation for its research activities and is fully accredited by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP). Additional information is available at http://www.cedars-sinai.edu/

Contact: Sandy Van

Cedars-Sinai Medical Center